TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH LYMPHOMA TYPEOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE
6.1. Overview
6.2. Peripheral T-cell Lymphoma
6.2.1. Cutaneous T-cell Lymphoma
6.2.2. Anaplastic Large Cell Lymphoma
6.2.3. Angio-immuno-blastic T-cell Lymphoma
6.2.4. Others
6.2.4.1. Intestinal T-cell Lymphoma
6.2.4.2. Follicular T-cell lymphoma
6.3. T-cell Lymphoblastic Lymphoma
7. GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY
7.1. Overview
7.2. Radiotherapy
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Stem Cell Transplantation
7.6. Others
8. GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America
9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global T-Cell Lymphoma Therapeutics Industry Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global T-Cell Lymphoma Therapeutics Industry Market,
9.7. Key developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2023
9.8.2. Major Players R&D Expenditure, 2023
10. COMPANY PROFILES
10.1. 4SC AG
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Acrotech Biopharma
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Affimed
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Bausch Health Companies Inc.
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Biocryst Pharmaceuticals Inc.
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Bristol-Myers Squibb Company
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Chipscreen Biosciences
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. CITIUS PHARMA
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. CSPC
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. CStone Pharmaceuticals
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Daiichi-Sankyo
10.11.1. Company Overview
10.11.2. Financial Overview
10.11.3. Products Offered
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 7 US: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 8 US: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 9 CANADA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 10 CANADA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 3 GERMANY: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 5 FRANCE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 6 FRANCE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 7 ITALY: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 8 ITALY: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 9 SPAIN: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 10 SPAIN: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 11 UK: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 12 UK: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 17 JAPAN: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 18 JAPAN: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 19 CHINA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 20 CHINA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 21 INDIA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 22 INDIA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 23 AUSTRALIA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 24 AUSTRALIA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 33 AFRICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 34 AFRICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY LYMPHOMA TYPE, 2019-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, BY THERAPY, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET
FIGURE 4 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY LYMPHOMA TYPE, 2023
FIGURE 5 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY THERAPY, 2023
FIGURE 6 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 7 NORTH AMERICA: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 EUROPE: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 ASIA-PACIFIC: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 REST OF THE WORLD: T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 GLOBAL T-CELL LYMPHOMA THERAPEUTICS INDUSTRY MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 12 4SC AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 4SC AG: SWOT ANALYSIS
FIGURE 14 ACROTECH BIOPHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ACROTECH BIOPHARMA: SWOT ANALYSIS
FIGURE 16 AFFIMED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 AFFIMED: SWOT ANALYSIS
FIGURE 18 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS
FIGURE 20 BIOCRYST PHARMACEUTICALS INC..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 BIOCRYST PHARMACEUTICALS INC..: SWOT ANALYSIS
FIGURE 22 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 24 CHIPSCREEN BIOSCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 CHIPSCREEN BIOSCIENCES: SWOT ANALYSIS
FIGURE 26 CITIUS PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 CITIUS PHARMA: SWOT ANALYSIS
FIGURE 28 CSPC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 CSPC: SWOT ANALYSIS
FIGURE 30 CSTONE PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 CSTONE PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 32 DAIICHI-SANKYO: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 DAIICHI-SANKYO: SWOT ANALYSIS
